Sugi Predict

Sugi Predict / Compounds / Gtp

Gtp

Gtp

SCHEMBL17367368

Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)C(O)[C@@H]2O)c(=O)[nH]1

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.81
▸ NT5E P21589 1/20 0.76
▸ KRAS P01116 2/20 0.76
▸ FUT5 Q11128 1/20 0.75
▸ P2RX3 P56373 2/20 0.71
▸ P2RY6 Q15077 2/20 0.71
▸ P2RY2 P41231 1/20 0.71
▸ P2RY4 P51582 1/20 0.71
▸ P2RY1 P47900 4/20 0.68
▸ ENPP1 P22413 2/20 0.68
▸ P2RX1 P51575 1/20 0.68
▸ P2RY11 Q96G91 1/20 0.68
▸ P2RX4 Q99571 1/20 0.68
▸ P2RY12 Q9H244 1/20 0.66
▸ IMPDH2 P12268 5/20 0.65
▸ IMPDH1 P20839 1/20 0.65
▸ DCPS Q96C86 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gtp SCHEMBL18271799 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL3333959 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL376140 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL18784960 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL376139 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL1304258 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL19691775 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL2593095 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL5809658 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL96708 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330065-A1 RelA Inhibitors for Biofilm Disruption DREXEL UNIVERSITY (US) 2023-10-19 — — US disclosed
US-20230250127-A1 MODIFIED mRNA 5'-CAP ANALOGS Nanjing GeneLeap Biotechnology Co., Ltd. (CN) 2023-08-10 — — US disclosed
US-11666555-B2 RelA inhibitors for biofilm disruption DREXEL UNIVERSITY (US) 2023-06-06 — — US disclosed
US-20180168208-A1 FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS, INCORPORATED (US) 2018-06-21 — — US disclosed
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2017-05-18 — — US disclosed
US-20170112948-A1 Inorganic-organic hybrid compound Karlsruher Institut für Technologie (DE) 2017-04-27 — — US disclosed
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160354493-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNATX, INC. 2016-12-08 — — US disclosed
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-01 — — US disclosed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 — — US disclosed
US-20150376219-A1 Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods ZHONG MINGHONG (US) 2015-12-31 — — US disclosed
US-20150376219-A1 Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods ZHONG MINGHONG (US) 2015-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885NT5E 32/4885KRAS 1439/4885
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885NT5E 32/4885KRAS 1439/4885
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885NT5E 32/4885KRAS 1439/4885
US-20230250127-A1 MODIFIED mRNA 5'-CAP ANALOGS RNGTT, RNMT, NSUN2 TGM2 4299/4885NT5E 338/4885KRAS 1524/4885
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TGM2 2234/4885NT5E 67/4885KRAS 1591/4885
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885NT5E 32/4885KRAS 1439/4885
US-11666555-B2 RelA inhibitors for biofilm disruption RELA, NFKBIA, NFKB1 TGM2 1947/4885NT5E 2992/4885KRAS 145/4885
US-20170112948-A1 Inorganic-organic hybrid compound SLCO4C1, SLCO2A1, SLCO1A2 TGM2 3027/4885NT5E 2746/4885KRAS 3753/4885
US-20160354493-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885NT5E 32/4885KRAS 1439/4885
US-20230330065-A1 RelA Inhibitors for Biofilm Disruption RELA, NFKBIA, NFKB1 TGM2 1947/4885NT5E 2992/4885KRAS 145/4885
US-20150376219-A1 Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods PNP, ATIC, NT5C3B TGM2 2919/4885NT5E 21/4885KRAS 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.